neurosurgical focus
C
ushing's disease (CD) is caused by a pituitary tumor secreting excess adrenocorticotropic hormone, resulting in downstream overproduction of cortisol. Adrenocorticotropic hormone-secreting pituitary adenomas are typically benign, and the mainstay of treatment in newly diagnosed patients with CD is transsphenoidal surgery (TSS). 1, [3] [4] [5] [7] [8] [9] [12] [13] [14] Following successful tumor resection, patients may ultimately regain normal pituitary function and experience long-term hormonal remission or even cures. 10 Medical and radiation-based therapies for CD are often reserved for patients who cannot undergo resection, or those with recurrent or refractory CD. A prior report by Patil et al. highlighted the incidence rate and several demographic factors that predicted national outcomes following TSS for CD in patients identified in the Nationwide Inpatient Sample (NIS) from 1993 to 2002, 11 but due to shifting demographics and ongoing innovations in health care, we sought to analyze more recent data to update this research and provide an accurate assessment of outcomes, complications, and patient demographic factors.
In the current study, we examined NIS data derived from 2002 to 2010 to evaluate outcomes following TSS in more than 5500 patients with CD. Predictor variables analyzed included patient demographic data, hospital characteristics, payer type, and admission type. Outcomes analyzed included the frequency of various complications, mortality, nonroutine discharge, length of stay (LOS), and hospital charges. Furthermore, we compared our analysis with previous reports to identify trends in complication rates, hospital outcomes, and factors influencing access to surgery.
methods patient sample
This study used longitudinal hospital inpatient discharge data from 2002 to 2010 in the Healthcare Cost and Utilization Project (HCUP) NIS database (http://www. hcup-us.ahrq.gov/nisoverview.jsp). This is the largest publicly available, all-payer inpatient care database in the US. As of 2010, the NIS database contained data from more than 1000 hospitals representing 20% of all US hospital discharges. To obtain national estimates, proper weights were applied as indicated in the HCUP-NIS guide for calculating NIS variances. 6 Admissions were identified using International Classification of Diseases, Ninth Revision; Clinical Modification (ICD-9-CM) codes for CD (255.00). Two populations were created for analysis. For the purpose of outcomes analysis after a pituitary transsphenoidal procedure, the first group of admissions was created from patients with CD who underwent a pituitary transsphenoidal procedure (biopsy [07.14] ; or any complication (either endocrine or nonendocrine). The second group of admissions was created from all patients with CD for the purpose of comparing the demographic data between patients who underwent TSS and those who did not.
Discrete patient predictors, including race (white, black, Hispanic, Asian Pacific Islander, Native American, other); payer status (Medicare, Medicaid, private insurance, selfpay, no charge); sex (male, female); admission source (emergency room [ER] , another hospital, other health facility including long-term care facilities, court/law enforcement, routine); and admission type (emergency, urgent, elective) were encoded as categorical variables in the NIS. Other patient predictors, such as number of comorbidities and age, were provided as continuous variables and recoded into categorical variables (comorbidities: 0, 1, or ≥ 2; and age: < 40, 40-60, or > 60 years). Hospital-level variables including bed size (small, ≤ 200; medium, 201-400; or large, > 400 beds), teaching status (nonteaching or teaching), and hospital region (Northeast, Midwest, South, or West) were included as categorical variables. Annual transsphenoidal procedure volume was calculated and reported in categorical tertiles (low, ≤ 2; medium, 2-5; or high, > 5 procedures) for analysis.
statistical Analysis
The primary goal was to assess socioeconomic, demographic, and hospital factors associated with surgical outcomes. Outcomes of interest were 1) endocrine and nonendocrine complications; 2) mortality; and 3) nonroutine discharge. Secondary outcomes included dichotomized prolonged inpatient LOS (> 3 days) and dichotomized incurred higher inpatient charges (defined as at or above the 90th percentile of adjusted total inpatient cost, $118,571.44). Additionally, it was of interest to evaluate patient and hospital predictors for specific endocrine complications (DI, CSF rhinorrhea, electrolyte abnormalities).
The predicting factors included patient-level factors: race, payment type, comorbidity, sex, and age; hospitallevel factors: region, teaching status, bed size, and procedure volume; and admission status-level factors: admission source and admission type. Hospital location (urban vs rural) was not included as a predicting factor because nearly all patients went to urban hospitals.
A univariate model (unadjusted model) was generated to validate variables to be used in multivariable regressions. Model 1 adjusted for patient-level factors; model 2 added on hospital-level factors to model 1; model 3 added on admission type to model 2; and model 4 added on admission type and source to model 2.
The descriptive result was estimated using the "surveymean" procedure for applying the survey weight. The association between predicting factors and outcome was assessed by the rate ratio estimated through multivariate Poisson regression (glimmix).
Statistical significance was defined as a p value < 0.05 for all analyses. All descriptive and regression analyses were performed using SAS software, version 9.4 (SAS Institute).
results patient sample
Between 2002 and 2010, there were 5579 transsphenoidal procedures (54 biopsies, 4254 partial resections, and 1271 total resections) for 5527 patients with CD identified in the NIS database. Of these patients, 1700 (30.76%) had procedures that resulted in at least one endocrine or nonendocrine complication; 1237 (22.38%) had procedures that resulted in an endocrine complication, 611 (11.06%) had nonendocrine complications, and 74 (1.34%) had both endocrine and nonendocrine complications (Table 1 ). There were 25 deaths after TSS, for a mortality incidence rate of 0.45%. The majority of patients were white and privately insured. The proportion of white patients who were privately insured was 78.34%, as compared with 60.21% of Hispanic patients with private insurance. Of the Hispanic patients, 20.64% had Medicare, compared with 3.61% of white patients (Table 2) . Medicare patients underwent a transsphenoidal procedure 2.68% of the time and Medicaid patients 0.90% of the time, compared with patients with private insurance/health maintenance organization (HMO), who obtained the surgery 9.71% of the time (Table 3) .
Most patients underwent TSS following elective admission, and were thus considered routine admissions for all age categories and payer types. Most procedures were performed at high procedural volume teaching hospitals in an urban location. See Table 3 for specific breakdown of patient-and hospital-level factors.
The most commonly occurring nonendocrine complications were postoperative neurological complications (6.98%) and mechanical ventilation (1.72%). Diabetes insipidus (14.78%) and electrolyte abnormalities (9.35%) were the most common endocrine complications ( Table 1) . The mortality rate after TSS for CD was 0.45% (Table 4) .
patient-level Factors
Payer Type and Outcome Following TSS for CD As shown in Table 5 , when compared with private insurance/HMO as a reference standard, patients with Medicaid had an increased risk of higher charges after adjusting for patient-level factors, hospital-level factors, and admission type (relative risk [RR] 1.93, 95% CI 1.10-3.41; p = 0.02); however, adding admission source into the model rendered Medicaid status insignificant. Medicare status also increased risk of higher charges before adjusting for admission status (RR 1.89, 95% CI 1.04-3.45; p = 0.04); however, the increased risk was mediated by admission type so it became nonsignificant when adjusting for admissions. Additionally, Medicare status increased the risk of nonendocrine complications (RR 2.24, 95% CI 1.15-4.38; p = 0.02). Medicare and Medicaid status were significant for mortality rate via univariate analysis, but the relationship was no longer present following multivariate analysis. Medicaid had almost double the incidence of electrolyte abnormalities, even after adjusting for patient, hospital, and admission predictors (RR 1.93, 95% CI 1.02-3.66; p = 0.04).
Race and Outcome Following TSS for CD
As compared with white patients, Hispanic patients had an increased rate of higher charges based on patientand hospital-level factors (RR 1.86, 95% CI 1.12-3.10; p = 0.02). However, this relationship disappeared when the model was adjusted for admission type or admission type/ source. Asian and Hispanic patients had a higher risk of nonendocrine complications calculated via univariate analysis, but the relationship did not hold under any of the 4 multivariate models tested. Asians had more than 10 times the incidence rate of CSF rhinorrhea after adjusting for all patient, hospital, and admission predictors 
hospital-level Factors
Hospital Bed Size and TSS Volume as Predictors of Outcome Following TSS for CD As shown in Table 6 , although high volume was protective in univariate analysis for total charges, nonendocrine complications, electrolyte abnormalities, endocrine complications, and total complications, volume failed to stay protective after multivariate analysis. Bed size was not a statistically significant predictor of any outcomes in multivariate analysis. and South (RR 1.86, 95% CI 1.39-2.49; p < 0.01) was also higher after adjusting for patient, hospital, and admission predictors.
Teaching Status and Outcomes Following TSS for CD
As compared with nonteaching hospitals, teaching hospitals had a significantly lower rate of higher hospital charges even after adjusting for patient, hospital, and admission predictors (RR 0.49, 95% CI 0.28-0.85; p = 0.01). Although teaching status was protective in univariate analysis for nonendocrine complications, endocrine complications, total complications, DI, and electrolyte abnormalities, the association was not maintained after multivariate analysis.
Admission status

Admission Status and Outcomes Following TSS for CD
As shown in Table 7 , when compared with elective admission type, patients with emergency admissions had a risk of higher hospital charges (RR 3.06, 95% CI 1.26-7.46; p = 0.01) and nonendocrine complications (RR 3.18, 95% CI 1.22-8.28; p = 0.02) even after adjusting for all patient, hospital, and admissions predictors. Emergency admission type was also predictive of electrolyte abnormalities (RR 3.26, 95% CI 1.39-7.66; p < 0.01) and higher LOS (RR 1.69, 95% CI 1.01-2.84; p = 0.05) when adjusted for patient-and hospital-level factors, but the relationship dissipated when adjusted for admission source.
discussion
We report an analysis of more than 5500 patients with CD who were treated with TSS, as extrapolated via survey weights from NIS data. This body of data represents nearly 20% of all inpatient admissions nationwide during the same time period. Our analysis of a variety of patient, payer, and hospital predictors resulted in many interesting findings pertaining to important TSS outcomes, including the incidence of complications, overall mortality and discharge type, LOS, and hospital charges. The findings derived from this study are in line with the findings from 11 According to our study, the overall mortality rate following TSS for CD was 0.45%. The incidence of nonendocrine complications was 11%, and the incidence of endocrine complications was 22%.
A major predictor of outcome following TSS for CD was payer status. Patients with Medicare and Medicaid had increased risk of higher hospital charges, and Medicare patients had more than double the rate of nonendocrine complications (RR 2.24, 95% CI 1.15-4.38; p = 0.02). Interestingly, we did not identify major health care disparities in outcome when analyzing according to race and controlling for other variables in the multivariate models tested. Although Hispanic patients had higher hospital charges, this did not hold up following adjustment for admission type, because more Hispanic patients were admitted through an ER. Similarly, age was not a major predictor of most outcomes following TSS, with the exception that patients with age < 40 years were at higher risk for developing DI.
According to our analysis, hospital bed size and TSS volume were not predictive of overall outcomes, a finding that has previously been shown to predict outcomes when analyzing patients with all pituitary adenoma subtypes, as reported by Barker et al. 2 Also interesting was that hospitals located in the western and southern US had increased overall LOS as compared with hospitals in the Northeast and that hospitals located in the western US reported worse endocrine and nonendocrine outcomes. Finally, teaching hospitals had approximately half the rate of incurring higher charges as compared with nonteaching hospitals. As expected, emergency admissions were associated with a higher incidence of nonendocrine complications, LOS, and hospital charges.
A central focus of our analysis was to determine how complication frequencies had changed since being previously reported by Patil et al. in 2007. 11 In general, rates for major complications from our study were reduced or stayed the same as compared with the prior analysis from 1993 to 2002. The incidence rate of DI and cases with one or more complications were nearly the same as previously reported, with frequencies of 14.78% and 30.76%, respectively. Mortality was slightly reduced from 0.7% to 0.45%. Additionally, the frequency of electrolyte abnormalities decreased from 12.5% to 9.35%. Admittedly, this comparison was restricted by limitations inherent in the NIS. For example, patients were simply identified as having CD, and no data were available to determine if they were newly diagnosed, recurrent, or previously treated. The total percentage of patients receiving TSS was fairly low, indicating that many of the patients recorded either had recurrent disease or had been previously treated, because TSS is the preferred first-line treatment for most newly diagnosed patients with CD. 10 Complication rates could have been affected by receiving TSS at different stages of the disease, or by receiving previous treatments. Furthermore, because the average LOS was 4.51 days and the NIS does not track patients after discharge, we were unable to differentiate between transient and permanent DI. Also, electrolyte abnormalities caused by DI may have been counted as a separate and distinct complication, which probably inflated our frequencies for both total complications and endocrine complications. However, because these limi tations were the same for the prior decade, 11 an overall decrease in both mortality and electrolyte abnormalities was still very promising.
We also discovered a general trend toward improvement for hospital outcomes since previous reports. An increasing number of patients had access to a larger sized facility (80% for Patil et al. 11 and 84.52% in our sample), and LOS was reduced from 5.5 days in the previous report to 4.51 days in our sample. Additionally, decreasing LOS could have an added benefit in terms of hospital charges, as Patil et al. showed that charges increase drastically with an increase in LOS. Surprisingly, we found that teaching hospital status was protective against higher hospital charges (RR 0.49). However, we were unable to determine if this contributes to a trend in overall improvement, because earlier reports found no significant correlation between hospital teaching status and charges. 2 How teaching hospitals correlated with lower charges in this case certainly warrants further investigation, considering the societal burden imposed by increasing health care costs coupled with a growing patient population.
We also sought to establish how demographic factors impacted a patient's likelihood of receiving TSS for CD, and identified payment type and advanced age as important factors. Despite a general trend toward improvement in outcomes, only 2.68% of patients with Medicare and 0.90% of patients with Medicaid received the surgery, compared with 9.71% of patients with private insurance ( Table 3 ). Considering that the large majority of Medicare patients are > 65 years old, this reduced access to surgery is also evident when grouping patients by age. Patients > 60 years old were also much less likely to receive surgery. Compared with 11.22% of patients < 40 years old, only 4.44% of patients 40-60 years old and 1.11% of patients > 60 years old underwent TSS, even though advanced age was not a significant predictor of any adverse outcome in our analysis.
It is important to note that there are other, less invasive therapies available for patients with CD that could affect these measurements. For example, patients opting for radiation therapy instead of TSS would lower these percentages, especially in elderly patients and others who may not be ideal surgical candidates. However, because TSS is the preferred treatment for CD with the best overall cure rate, 10 the number of patients forgoing TSS for radiation therapy was probably too small to account for the drastic reduction in access among patients > 60 years old.
We compared complication frequencies and hospital outcomes following TSS for CD in the US with the findings in a previous report by Patil et al. 11 We found that frequencies for DI and cases with one or more complications were nearly the same, whereas mortality and electrolyte abnormalities were reduced. Hospital outcomes also showed general improvement, with an overall reduction in LOS and increased access to larger facilities.
conclusions
Our review of NIS data in more than 5500 patients treated surgically for CD pointed to major outcome disparities predicted primarily by payer status, admission type, and hospital region. The findings from this and prior studies may help to identify and target key barriers in equal access to health care and major health care disparities in patients receiving both nonsurgical and specialty surgical treatment for CD. Patients with Medicare or Medicaid and those treated in hospitals in the western US may collectively be at a disadvantage compared with patients with private insurance or in other regions of the US. Identification and targeting of such barriers to quality health care in patients with CD may help optimize patient outcomes on a national level and present an opportunity to improve access for high-risk patient groups to specialty centers of excellence. 
